A Phase 1 Study of LY2584702 in Japanese Patients With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2018
At a glance
- Drugs LY 2584702 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 20 May 2016 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information; JapicCTI101329)
- 17 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Sep 2011 Planned end date changed from 1 Nov 2010 to 1 Mar 2012 as reported by ClinicalTrials.gov.